71610 0211 60
Gabapentin Capsule
Product Images NDC 71610-211
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-211). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Aphena Pharma Solutions (TN)
Figure 1 (Image 01)
This appears to be a chart representing the Mean Pain Score for different treatment conditions. The chart includes a fixed dose and titration period for the medication Parkod, as well as a placebo and Gabapentin at 3600mg per day. The chart shows the pain score at baseline and after several weeks of treatment.*
Figure 2 (Image 02)
This is a graph representing the results of a 4-week fixed dose period study on the effects of Gabapentin in reducing pain. The x-axis shows the weeks of the study and the y-axis represents the mean pain scores. There are four groups represented, a placebo group, a group receiving 1800mg/day of Gabapentin, a group receiving 2400mg/day of Gabapentin, and a baseline group. The graph shows that both doses of Gabapentin led to a decrease in mean pain score over the four weeks.*
Figure 3 (Image 03)
Cockcroft And Gault Equation (Image 04)
Gabapentin Structural Formula (Image 05)
Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
